Zacks: BIOFRONTERA AG/ADR (NASDAQ:BFRA) Receives Consensus Rating of “Strong Buy” from Analysts
BIOFRONTERA AG/ADR (NASDAQ:BFRA) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Brokerages have set a 12 month consensus price objective of $21.75 for the company, according to Zacks. Zacks has also assigned BIOFRONTERA AG/ADR an industry rank of 48 out of 256 based on the ratings given to related companies.
Separately, Lake Street Capital dropped their price objective on shares of BIOFRONTERA AG/ADR from $24.00 to $21.00 and set a “buy” rating on the stock in a report on Wednesday, July 10th.
BIOFRONTERA AG/ADR (NASDAQ:BFRA) last released its quarterly earnings results on Wednesday, May 29th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.03. BIOFRONTERA AG/ADR had a negative net margin of 62.81% and a negative return on equity of 95.81%. The business had revenue of $7.73 million for the quarter.
BIOFRONTERA AG/ADR Company Profile
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis.
See Also: Diversification in Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BIOFRONTERA AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOFRONTERA AG/ADR and related companies with MarketBeat.com's FREE daily email newsletter.